Cargando…

Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience

BACKGROUND: Ripretinib was recently approved for the fourth-line targeted therapy for advanced gastrointestinal stromal tumor (GIST) refractory to imatinib, sunitinib, and regorafenib based on the pivotal INVICTUS phase III study. The INVICTUS study demonstrated significantly improved median progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Li-Ching, Huang, Wen-Kuan, Yen, Chueh-Chuan, Yang, Ching-Yao, Sung, Meng-Ta, Wong, Natalie S. M., Chua, Daniel T. T., Lee, Sarah W. M., Chen, Jen-Shi, Yeh, Chun-Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277435/
https://www.ncbi.nlm.nih.gov/pubmed/35847924
http://dx.doi.org/10.3389/fonc.2022.883399